Biotage publishes prospectus for admission to trading of shares, to be issued as part of the acquisition of Astrea Bioseparations, on Nasdaq Stockholm
Kurs & Likviditet
Prenumeration
Kalender
| Tid* | ||
| 2026-02-19 | 14:00 | Bokslutskommuniké 2025 |
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-16 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-24 | - | Årsstämma |
| 2025-04-24 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | 14:00 | Bokslutskommuniké 2024 |
| 2024-10-23 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-26 | - | X-dag ordinarie utdelning BIOT 1.60 SEK |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-25 | - | Årsstämma |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-28 | - | X-dag ordinarie utdelning BIOT 1.60 SEK |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-04-27 | - | Årsstämma |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-02 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | X-dag ordinarie utdelning BIOT 1.55 SEK |
| 2022-04-28 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-11 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | X-dag ordinarie utdelning BIOT 1.50 SEK |
| 2021-04-28 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-12 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-05 | - | X-dag ordinarie utdelning BIOT 0.00 SEK |
| 2020-06-04 | - | Årsstämma |
| 2020-04-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Extra Bolagsstämma 2019 |
| 2019-11-05 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-25 | - | X-dag ordinarie utdelning BIOT 1.50 SEK |
| 2019-04-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-24 | - | Årsstämma |
| 2019-02-07 | - | Bokslutskommuniké 2018 |
| 2018-11-06 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-16 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-27 | - | X-dag ordinarie utdelning BIOT 1.40 SEK |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-26 | - | Årsstämma |
| 2018-02-08 | - | Bokslutskommuniké 2017 |
| 2017-11-02 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-28 | - | X-dag ordinarie utdelning BIOT 1.25 SEK |
| 2017-04-27 | - | Årsstämma |
| 2017-02-09 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-11 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | X-dag ordinarie utdelning BIOT 1.00 SEK |
| 2016-04-29 | - | X-dag bonusutdelning BIOT 0.25 |
| 2016-04-28 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-28 | - | Årsstämma |
| 2016-02-11 | - | Bokslutskommuniké 2015 |
| 2015-10-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-29 | - | X-dag ordinarie utdelning BIOT 0.75 SEK |
| 2015-04-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-28 | - | Årsstämma |
| 2015-02-12 | - | Bokslutskommuniké 2014 |
| 2014-10-30 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-14 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-29 | - | X-dag ordinarie utdelning BIOT 0.60 SEK |
| 2014-04-28 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-28 | - | Årsstämma |
| 2014-02-13 | - | Bokslutskommuniké 2013 |
| 2013-10-25 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-15 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-26 | - | X-dag ordinarie utdelning BIOT 0.50 SEK |
| 2013-04-25 | - | Årsstämma |
| 2013-04-25 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-12 | - | Bokslutskommuniké 2012 |
| 2012-10-26 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-17 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-27 | - | X-dag ordinarie utdelning BIOT 0.40 SEK |
| 2012-04-26 | - | Kvartalsrapport 2012-Q1 |
| 2012-04-26 | - | Årsstämma |
| 2012-02-09 | - | Bokslutskommuniké 2011 |
| 2011-10-26 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-17 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | X-dag ordinarie utdelning BIOT 0.25 SEK |
| 2011-04-27 | - | Årsstämma |
| 2011-04-27 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-10 | - | Bokslutskommuniké 2010 |
| 2010-10-26 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-13 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-30 | - | X-dag ordinarie utdelning BIOT 0.20 SEK |
| 2010-04-29 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-11 | - | Bokslutskommuniké 2009 |
| 2009-10-27 | - | Kvartalsrapport 2009-Q3 |
| 2009-08-14 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-28 | - | X-dag ordinarie utdelning BIOT 0.20 SEK |
| 2009-04-27 | - | Kvartalsrapport 2009-Q1 |
| 2009-04-27 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Uppsala, Sweden – 30 May 2023 – As previously announced, Biotage AB (publ) (“Biotage”) has entered into agreements to acquire all of the shares in Astrea Bioseparations (“Astrea”) from Gamma Biosciences (“Gamma”) [1], a life sciences tools platform created by KKR. The acquisition also includes the shares held by certain minority investors [2] in the Astrea group (together with Gamma, the “Sellers”, and together with the acquisition of Astrea, the “Transaction”). The Transaction is expected to be completed on or around 1 June 2023. As part consideration for the Transaction, the board of directors of Biotage will, by virtue of an authorization granted by the Annual General Meeting held on 27 April 2023, resolve to issue 13,954,103 ordinary shares to the Sellers.
A prospectus regarding admission to trading of the ordinary shares, to be issued as part of the Transaction, on Nasdaq Stockholm, has been approved and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website, www.biotage.com.
About Biotage
Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.
Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.
Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs over 500 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.
Website: www.biotage.com
Contacts
Tomas Blomquist, President and CEO
Tel: 0705 23 01 63, tomas.blomquist@biotage.com
The information was submitted for publication, through the agency of the contact person set out above, at 2023-05-30 10:50 CEST.
[1] Held through Gamma Biosciences Newco Limited and Gamma Biosciences Newco 2 Limited, two entities controlled by KKR.
[2] Held through Nano Hold Co., LLC.